A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• Histologically confirmed, locally advanced, not amenable to curative therapy, or metastatic NSCLC
• ALK-rearrangement confirmed by the Food and Drug Administration (FDA) approved test
• NSCLC that has failed crizotinib treatment
• Measurable disease as defined by RECIST v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (<=) 2
• Adequate hematologic, hepatic and renal function

Exclusion Criteria

• Prior therapy with ALK inhibitor other than crizotinib
• Brain or leptomeningeal metastases that are symptomatic and/or requiring treatment
• History of serious cardiac dysfunction
• History of or current active infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
• Clinically significant gastrointestinal abnormality that would affect absorption of the drug
• Pregnant or lactating women